| Literature DB >> 19877685 |
F Ivy Carroll1, Philip Abraham, Paul K Gong, Ramakrishna R Pidaparthi, Bruce E Blough, Yingni Che, Amber Hampton, Melinda Gunnell, Jackson O Lay, Eric C Peterson, S Michael Owens.
Abstract
In addition to addiction, the repeated use of (+)-methamphetamine [(+)-METH], (+)-amphetamine [(+)-AMP], or (+/-)-3,4-methylenedioxymethamphetamine ((+/-)-MDMA, commonly called ecstasy) can lead to life-threatening medical problems including cardiovascular injury, severe depression, and psychosis. Currently, there are no specific pharmacotherapies to treat these medical problems. In this study, we report the design and synthesis of two haptens, (S)-(+)-3-(9-carboxynonyloxy)methamphetamine (3a, (+)-METH MO10) and (S)-(+)-3-(5-carboxypentyloxy)methamphetamine (3b, (+)-METH MO6), and their use in generating high affinity (low K(D) value) monoclonal antibodies (mAbs) against (+)-METH, (+)-AMP, and/or (+)-MDMA. On the basis of results from the determination of mAb K(D) values and ligand specificity, the mAbs generated from hapten 3a showed the greatest promise for generating active and passive immunotherapies for treating overdose or addiction from (+)-METH-like stimulants.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19877685 PMCID： PMC2787402 DOI： 10.1021/jm901134w
Source DB: PubMed Journal: J Med Chem ISSN： 0022-2623 Impact factor: 7.446